Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human IGF-II, Fc Tag, Avi Tag (Avitag™), 200µg  

Recombinant Biotinylated Human IGF-II, Fc Tag, Avi Tag (Avitag™), 200µg

MABSol® Recombinant Biotinylated Human IGF-II (Ala 25 - Glu 91), expressed from human HEK293 cells, Avi tag (Avitag™), Fc Tag

Synonym
recombinant, human, biotinylated, protein, IGF2, C11orf43, FLJ22066, FLJ44734, IGF-II, PP9974, Somatomedin-A, Insulin-like growth factor 2

More details

IG2-H82F9-200

Availability: within 7 days

1 380,00 €

Background
Insulin-like growth factor 2 (IGF-2) is also known as Somatomedin-A, IGF-II, PP9974, and is one of three protein hormones that share structural similarity to insulin. IGF-2 exerts its effects by binding to the IGF-1 receptor. IGF2 may also bind to the IGF-2 receptor (also called the cation-independent mannose 6-phosphate receptor), which acts as a signalling antagonist; that is, to prevent IGF2 responses. The major role of IGF2 is as a growth promoting hormone during gestation. In the process of Folliculogenesis, IGF2 is created by Theca cells to act in an autocrine manner on the theca cells themselves, and in a paracrine manner on Granulosa cells in the ovary. IGF2 promotes granulosa cell proliferation during the follicular phase of the menstrual cycle, acting alongside Follicle Stimulating Hormone (FSH). After ovulation has occurred, IGF-2 promotes progesterone secretion during the luteal phase of the menstrual cycle together with Luteinizing Hormone (LH). Thus, IGF2 acts as a Co-hormone together with both FSH and LH. IGF-2 may play a key role in memory and could potentially be used to treat Alzheimer's Disease. It is sometimes produced in excess in islet cell tumours, causing hypoglycemia. Doege-Potter syndrome is a paraneoplastic syndrome in which hypoglycemia is associated with the presence of one or more non-islet fibrous tumors in the pleural cavity. has been shown to interact with IGFBP3 and Transferrin.

Source
Recombinant Biotinylated Human IGF-II, Avitag,Fc Tag (IG2-H82F9) is expressed from human 293 cells (HEK293). It contains AA Ala 25 - Glu 91 (Accession # P01344-1).
Predicted N-terminus: Gly

Molecular Characterization
This protein carries an Avi tag (Avitag™) at the N-terminus, followed by a human IgG1 Fc tag.
The protein has a calculated MW of 35.3 kDa. As a result of glycosylation, the protein migrates as 40 kDa under reducing (R) condition, and 66 kDa under non-reducing (NR) condition (SDS-PAGE).

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

References

(1) MacRae, Fiona , 2011, Daily Mail (London).
(2) Balduyck B,et al., 2006, J Thorac Oncol 1 (6): 588–90.
(3) Storch, S, et al., 2001, FEBS Lett. (Netherlands) 509 (3): 395–8.
(4) Buckway, C K, et al., 2001, J. Clin. Endocrinol. Metab. (United States) 86 (10): 4943–50.
(5) Twigg, S M, Baxter R C, 1998, J. Biol. Chem. (UNITED STATES) 273 (11): 6074–9.
(6) Firth, S M; Ganeshprasad U, Baxter R C, 1998, J. Biol. Chem. (UNITED STATES) 273 (5): 2631–8.

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.